Equilenin

A naturally occurring steroidal estrogen

Equilenin
Equilenin
Chemical nomenclature
IUPAC name	(13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
Identifiers
CAS Number	517-09-9
PubChem	5281039
DrugBank	DB04573
ChemSpider	4447590
UNII	3E3V44J6Z5
KEGG	D04265
ChEMBL	1201328

Equilenin is a naturally occurring steroidal estrogen found in the urine of pregnant mares. It is one of the components of conjugated equine estrogens (CEEs), which are used in hormone replacement therapy (HRT) for menopausal women. Equilenin is a unique estrogen because it is not found in humans but is instead derived from equine sources.

Structure and Properties

Equilenin is a steroid with the chemical formula C18H18O2. It is characterized by its polycyclic structure, which includes a phenanthrene core. The molecule has hydroxyl groups at the 3 and 17 positions, which are critical for its estrogenic activity. The presence of these hydroxyl groups allows equilenin to bind to estrogen receptors in the body, mimicking the effects of endogenous estrogens such as estradiol.

Pharmacology

Equilenin acts as an agonist of the estrogen receptor, which is a nuclear receptor that regulates the expression of genes involved in the development and maintenance of female reproductive tissues. By binding to these receptors, equilenin can exert estrogenic effects, such as the regulation of the menstrual cycle and the maintenance of bone density.

Clinical Use

Equilenin is primarily used as part of conjugated equine estrogens in hormone replacement therapy. CEEs are prescribed to alleviate symptoms of menopause, such as hot flashes, vaginal dryness, and osteoporosis. The use of equilenin and other equine estrogens in HRT has been the subject of extensive research and debate, particularly concerning the risks and benefits of long-term estrogen therapy.

Biosynthesis

Equilenin is synthesized in the ovaries of pregnant mares. It is excreted in their urine, from which it is isolated and purified for pharmaceutical use. The biosynthesis of equilenin involves the conversion of cholesterol into pregnenolone, followed by a series of enzymatic reactions that produce the final estrogenic compound.

History

The discovery of equilenin dates back to the early 20th century when researchers began to explore the hormonal composition of mare urine. It was first isolated and identified as a distinct estrogenic compound in the 1930s. Since then, it has been used in various formulations of hormone replacement therapy.

Safety and Side Effects

Like other estrogens, equilenin can have side effects, particularly when used in high doses or for extended periods. Common side effects include nausea, breast tenderness, and headaches. There is also an increased risk of certain conditions, such as breast cancer and thromboembolism, associated with estrogen therapy.

Also see

• Estrogen
• Hormone replacement therapy
• Menopause
• Estradiol
• Conjugated equine estrogens

Equilenin

• Bachmann's total synthesis of equilenin
  Bachmann's total synthesis of equilenin